Abivax ’s ABX464 found to reduce HIV viral reservoir in blood
Abivax has reported positive top-line data from the first cohort of Phase IIa ABX464-005 clinical trial of its drug candidate ABX464 in patients with HIV.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Clinical Trials | Pharmaceuticals